NCT02013245View on ClinicalTrials.gov

Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

November 30, 2014

Conditions
TuberculosisHealthy
Interventions
BIOLOGICAL

MTBVAC live vaccine

Live-attenuated Mycobacterium tuberculosis vaccine

BIOLOGICAL

Commercially available BCG live vaccine

Live-attenuated Mycobacterium bovis vaccine

Trial Locations (1)

1011

Centre Hospitalier Universitaire Vaudois, Lausanne

Sponsors

Lead Sponsor

Biofabri, S.L
All Listed Sponsors
collaborator

Universidad de Zaragoza

OTHER

collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

collaborator

TuBerculosis Vaccine Initiative

OTHER

lead

Biofabri, S.L

INDUSTRY

NCT02013245 - Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine. | Biotech Hunter | Biotech Hunter